Halozyme Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen I. Torley
- Full Time Employees
- 423
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12390 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Mar 16, 2004
- CIK
- 0001159036
- Website
- halozyme.com
- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Company News
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,191,600.00 in Stock
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in Stock
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Why Women-Run Companies Deserve a Place in Your Portfolio
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Here’s Why
Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Bank of America Corp DE Makes New $214.50 Million Investment in Halozyme Therapeutics, Inc. $HALO
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)